Andrei‐Mircea Catarig

Author

Also Known As

A Catarig, A M Catarig, A.-M. Catarig, A.‐M. Catarig, ANDREI-MIRCEA CATARIG, Andrei-Mircea Catarig, Andrei‐Mircea Catarig

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)The University of Texas Southwestern Medical Center Novo Nordisk (India)Aarhus University Hospital Steno Diabetes Centers

About

Andrei‐Mircea Catarig is an author at Novo Nordisk (Denmark) specializing in medicine, diabetes, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	743
2	Diabetes	3	3	717
3	Pharmacology	3	3	667
4	Health Sciences	1	1	76
5	Diabetes Complications	1	1	376

Andrei‐Mircea Catarig

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg, Diabetes & Metabolism Diabetes ManagementDiabetesPharmacologyType 2Pharmacotherapy	2019	376
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial Ildiko Lingvay, Andrei‐Mircea Catarig, Juan P. Frías, The Lancet Diabetes & Endocrinology Diabetes ManagementSustain 8MedicineDiabetesType 2	2019	265
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial Rory J. McCrimmon, Andrei‐Mircea Catarig, Juan P. Frías, Diabetologia	2020	135
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial Marc P. Bonaca, Andrei‐Mircea Catarig, Kim Christian Houlind, The Lancet Metabolic SyndromeDiabetes ManagementPhysical ActivityHealth SciencesCardiovascular Disease	2025	76
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study Neda Rajamand Ekberg, Ulrik Bodholdt, Andrei‐Mircea Catarig, Primary care diabetes	2021	56
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups Jean‐François Yale, Ulrik Bodholdt, Andrei‐Mircea Catarig, BMJ Open Diabetes Research & Care	2022	44
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study Gottfried Rudofsky, Andrei‐Mircea Catarig, Lucie Favre, Diabetes Research and Clinical Practice	2021	42
Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study Patrick Holmes, Heather Elizabeth Bell, Karan Bozkurt, Diabetes Therapy	2021	37
Use of once‐weekly semaglutide in patients with type <scp>2</scp> diabetes in routine clinical practice: Results from the <scp>SURE C</scp> anada multicentre, prospective, observational study Jean‐François Yale, Andrei‐Mircea Catarig, Katrine Grau, Diabetes Obesity and Metabolism	2021	34
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the <scp>SURE</scp> Italy observational study Raffaele Napoli, Cesare Berra, Andrei‐Mircea Catarig, Diabetes Obesity and Metabolism	2023	27

Page 1